Aug 17, 2007 by Brian Orelli, PhDFDA's Rigor May Boost SalesThe confidence gained from stricter rules could translate into more prescriptions.
Aug 17, 2007 by Brian Orelli, PhDFewer Drug Approvals? Buy!Stricter standards at the FDA could create a Foolish opportunity.
Aug 16, 2007 by Brian Orelli, PhDMore Drugmaker Growth Without the FDAAll that high-tech equipment has to come from somewhere.
Aug 16, 2007 by Brian Orelli, PhDNovacea's (Statistically) Significant ChangeThe pharamceutical increases the number of subjects in its latest clinical trial.
Aug 15, 2007 by Brian Orelli, PhDBuffett's Drug DealsBerkshire invests more in battered pharmaceutical and medical stocks.
Aug 14, 2007 by Brian Orelli, PhDDrugmaker Growth Without the FDABuy stocks in the companies that support the drugmakers.
Aug 13, 2007 by Brian Orelli, PhDLittle Drug, Big SalesAbraxis draws hefty revenue from its nanoparticle pill.
Aug 10, 2007 by Brian Orelli, PhDOmrix Prepares to Stop the BleedingFDA approvals should put a halt to declining sales.
Aug 9, 2007 by Brian Orelli, PhDAcquisition Raises BarrThe integration of Pliva is going along nicely.
Aug 8, 2007 by Brian Orelli, PhDIs Indevus Headed to the Black?Two new drugs should help turn things around.
Aug 8, 2007 by Brian Orelli, PhDOnyx Is Almost ThereThe pharma's loss narrows for the quarter, and things should improve in the months to come.
Aug 6, 2007 by Brian Orelli, PhDHopeful Investors Stoke Pharmion's PriceNew trials show its drug can give patients additional months to live.
Aug 6, 2007 by Brian Orelli, PhDCongress' Delay May Hurt DrugmakersThe reauthorization of the Prescription Drug User Fee Act is delayed.
Aug 6, 2007 by Brian Orelli, PhDCheap Drugs on the FarmThe House approves a prescription-drug import provision.
Aug 3, 2007 by Brian Orelli, PhDExtrinsic Growth From InvernessAcquiring six companies in a year and a half, oh my!
